Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Emblem. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Emblem's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Emblem has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Emblem's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Emblem's earnings growth to the Canada market average as no estimate data is available.
Unable to compare Emblem's revenue growth to the Canada market average as no estimate data is available.
Unable to determine if Emblem is high growth as no earnings estimate data is available.
Unable to determine if Emblem is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Emblem's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Nicholas Dean also known as Nick has been Chief Executive Officer and President of Emblem Corp. since December 1, 2017. Mr. Dean has more than 12 years of consumer marketing and leadership experience including extensive work with highly respected pharmaceutical and healthcare brands. He worked with KBS Canada, a fully integrated creative agency with offices in Toronto and Montreal, where he led KBS through two mergers and a number of substantial client wins, resulting in significant bottom and top-line growth. He has been a Director of Emblem Corp. since February 2018. Mr. Dean earned his MBA from the Richard Ivey School of Business and holds his Bachelor of Commerce Degree from McMaster University.
Insufficient data for Nick to compare compensation growth.
Nick's remuneration is about average for companies of similar size in Canada.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Emblem management team is less than 2 years, this suggests a new team.
CEO, President & Director
Chief Financial Officer
Head of Investor Relations
General Counsel & Secretary
Chief Marketing Officer
Chief Strategy Officer
President of Medical
Board of Directors Tenure
Average tenure of the
board of directors in years:
The average tenure for the Emblem board of directors is less than 3 years, this suggests a new board.
What Kind Of Shareholder Owns Most Emblem Corp. (CVE:EMC) Stock?
Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Our analysis of the ownership of the company, below, shows that. … institutions own shares in the company
When Will Emblem Corp (CVE:EMC) Become Profitable?
produces, distributes, and sells medical cannabis and cannabis derivatives in Canada. … The company’s loss has recently broadened since it announced a -CA$12.1m loss in the full financial year, compared to the latest trailing-twelve-month loss of -CA$23.3m, moving it further away from breakeven. … I’ve put together a brief outline of industry analyst expectations for EMC, its year of breakeven and its implied growth rate
Is Emblem Corp's (CVE:EMC) Balance Sheet Strong Enough To Weather A Storm?
While small-cap stocks, such as Emblem Corp (CVE:EMC) with its market cap of CA$192m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. … Evaluating financial health as part of your investment thesis is
produces, distributes, and sells medical cannabis and cannabis derivatives in Canada. … The company’s loss has recently broadened since it announced a -CA$12.10m loss in the full financial year, compared to the latest trailing-twelve-month loss of -CA$13.44m, moving it further away from breakeven? … View our latest analysis for Emblem
Are Emblem Corp's (CVE:EMC) Interest Costs Too High?
While small-cap stocks, such as Emblem Corp (CVE:EMC) with its market cap of CA$171.72m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn.
EMC’s forecasted bottom line growth is an exceptional triple-digit, driven by underlying sales, which is expected to more than double, over the next few years. … Since net income isn’t artificially inflated by one-off initiatives such as cost-cutting, we know this profit growth is more likely to be sustainable. … Since net income isn’t artificially inflated by one-off initiatives such as cost-cutting, we know this profit growth is more likely to be sustainable.
AEZS is expected to deliver a buoyant earnings growth over the next couple of years of 36.84%, bolstered by a significant revenue which is expected to more than double. … XDC is expected to deliver a triple-digit high earnings growth over the next couple of years, bolstered by an equally impressive revenue growth of 71.62%. … TSX:XDC Future Profit Mar 24th 18 For more financially robust companies with high growth potential to enhance your portfolio, explore this interactive list of fast growing companies.
Emblem Corp. produces, distributes, and sells medical cannabis and cannabis derivatives in Canada. The company also operates medical cannabis education centers to provide education services for making informed decisions about medical cannabis treatment options to physicians and patients. In addition, it provides various accessories. Emblem Corp. has a strategic partnership with GreenSpace Brands to develop and commercialize cannabidiol infused health and beauty products. The company is headquartered in Toronto, Canada. As of March 14, 2019, Emblem Corp. operates as a subsidiary of Aleafia Health Inc.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.